About Us

De-Fib is a group of students and faculty concerned about the role of drug companies in medical education, patient care, and research. We provide resources to the Rochester medical community and the medical community-at-large to encourage productive debate of the ethics associated with pharmaceutical industry interactions.

About Our Name: De-Fib

De-Fib stands for Demanding Evidence, Forgoing Industry Bias. Our group name reflects our commitment to evidence-based medicine and our concern that interactions with the pharmaceutical industry may compromise our ability to provide evidence-based healthcare.

Our Goals

To ban drug company detailers (pharm rep marketers) from all University of Rochester hospitals and affiliated medical centers.
To provide objective insight concerning the negative impact irresponsible medical and pharmaceutical interactions can have on patient care, our US healthcare system, and the medical profession.
To help all medical professionals be more responsible in our interactions with the pharmaceutical industry.


	UPDATES

	New Course for FDA Marcia Angell, former editor of the NEJM, outlines 7 steps that need to be taken to ensure that medications released on the US market are safe and effective. Change for PMAs April 1st JAMA article outlines 10 rigorous recommendations to mitigate, and ultimately sever, ties between professional medical associations (PMAs) and the pharmaceutical industry. Let the Sun Shine Senate reintroduces Physician Payments Sunshine Act (S. 301), a bill requiring disclosure of all Industry payments > $100 to physicians into a public online database.

[ Home ] [ The Issues ] [ Medical Literature ] [ Resources ] [ In The News ]

[ Past Updates ] [ Action ] [ Members ] [ Join De-Fib ] [ Contact Us ]

Organized by University of Rochester School of Medicine Students and Faculty